Scott
Moomaw
Chief Commercial Officer
Scott Moomaw, MBA joined Liquidia in 2020 where he serves as Chief Commercial Officer (CCO). Scott is a seasoned leader in biopharmaceuticals with extensive experience launching products and developing commercial strategies and organizations. He joined Liquidia from RareGen, which he co-founded, to commercialize Treprostinil Injection for pulmonary arterial hypertension (PAH). Prior to RareGen, Scott was Vice President of Marketing at Opko Health and United Therapeutics where he was responsible for Remodulin® (parenteral treprostinil), Tyvaso® (inhaled treprostinil) and Orenitram® (oral treprostinil) for PAH. Scott also held a variety of sales and marketing roles of increasing responsibility at Eli Lilly for over 10 years. He holds a Master of Business Administration from the University of Michigan and a Bachelor of Science from Miami University.
Scott Moomaw, MBA joined Liquidia in 2020 where he serves as Chief Commercial Officer (CCO). Scott is a seasoned leader in biopharmaceuticals with extensive experience launching products and developing commercial strategies and organizations. He joined Liquidia from RareGen, which he co-founded, to commercialize Treprostinil Injection for pulmonary arterial hypertension (PAH). Prior to RareGen, Scott was Vice President of Marketing at Opko Health and United Therapeutics where he was responsible for Remodulin® (parenteral treprostinil), Tyvaso® (inhaled treprostinil) and Orenitram® (oral treprostinil) for PAH. Scott also held a variety of sales and marketing roles of increasing responsibility at Eli Lilly for over 10 years. He holds a Master of Business Administration from the University of Michigan and a Bachelor of Science from Miami University.